Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early lung ultrasound-guided versus guideline-based Curosurf administration in premature infants with respiratory distress syndrome
2022-003106-72Phase 4Active
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: Intubation rate within the first 72 hours of life. Started Feb 2023; status: active.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2022-003106-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003106-72.